Save time and money with
Med Tech Market Research

MedTech Business intelligence
supplied through Trade Tracker, Research and Markets and GlobalData

Hemophilia — Pipeline Assessment and Market Forecasts to 2017

The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders.

Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData’s analysis suggests that the global hemophilia therapeutics market was valued at $6.5 billion in 2009.

It is expected to increase at a Compound Annual Growth Rate (CAGR) of 5.8% from $6.5 billion in 2009 to $10.4 billion by 2017. This slow growth of 5.8% is primarily attributed to a low diagnosis rate and the high cost of therapy.

The safety and efficacy profiles of the existing therapies are moderate. The major treatments for hemophilia A include recombinant factor VIII drugs such as NovoSeven, Kogenate, Advate, ReFacto, Xyntha, Feiba and others for severe hemophilia cases. For mild to moderate hemophilia cases, DDAVP (desmopressin), which stimulates the release of factor VIII and also increases the level of proteins in the blood, is used. For hemophilia B, the most widely used branded drug is BeneFIX, a clotting factor from Pfizer Inc.

Scope

The report provides information on the key drivers and challenges of the hemophilia market. Its scope includes:

• Annualized global hemophilia market revenues data from 2001 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include Recombinant coagulation factors (VIIa, VIII,IX), plasma derived coagulation factors, thrombin generation, gene therapy, stem cell therapy, fast acting recombinant Factor VIIa, long acting Factor VIIa and monoclonal antibodies.
• Analysis of the current and future competition in the global hemophilia market. Key market players covered are Baxter Healthcare Corporation, Novo Nordisk, Bayer Healthcare Pharmaceuticals, Pfizer Inc, PTC Therapeutics Inc., Recloy N.V., Ipsen S.A and Biogen Idec Inc.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the hemophilia therapeutics market.

Reasons to Buy

The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global hemophilia market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global hemophilia market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global hemophilia market landscape? — Identify, understand and capitalize.

Buy now >>

To top